Biotech as a sector has had an interesting year. A handful of botched clinical trials at the beginning of the year made for rocky investment performance at some big name firms. Public opinion of the pharmaceutical industry also hit new lows amid drug pricing scandals. But RA Capital, a $1.1 billion biotech investment firm remains upbeat on the sector.

&quo